ATE429241T1 - Verfahren zur regulierung der stickstoffmonoxid- erzeugung - Google Patents

Verfahren zur regulierung der stickstoffmonoxid- erzeugung

Info

Publication number
ATE429241T1
ATE429241T1 AT97949565T AT97949565T ATE429241T1 AT E429241 T1 ATE429241 T1 AT E429241T1 AT 97949565 T AT97949565 T AT 97949565T AT 97949565 T AT97949565 T AT 97949565T AT E429241 T1 ATE429241 T1 AT E429241T1
Authority
AT
Austria
Prior art keywords
nitrogen monoxide
monoxide generation
regulating nitrogen
regulating
generation
Prior art date
Application number
AT97949565T
Other languages
English (en)
Inventor
Anthony Troutt
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21978190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE429241(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE429241T1 publication Critical patent/ATE429241T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97949565T 1996-11-27 1997-11-21 Verfahren zur regulierung der stickstoffmonoxid- erzeugung ATE429241T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5252596P 1996-11-27 1996-11-27
PCT/US1997/021451 WO1998023284A1 (en) 1996-11-27 1997-11-21 Method of regulating nitric oxide production

Publications (1)

Publication Number Publication Date
ATE429241T1 true ATE429241T1 (de) 2009-05-15

Family

ID=21978190

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97949565T ATE429241T1 (de) 1996-11-27 1997-11-21 Verfahren zur regulierung der stickstoffmonoxid- erzeugung

Country Status (8)

Country Link
US (1) US6083906A (de)
EP (1) EP0959897B1 (de)
JP (1) JP2001506982A (de)
AT (1) ATE429241T1 (de)
AU (1) AU7408998A (de)
DE (1) DE69739375D1 (de)
ES (1) ES2326347T3 (de)
WO (1) WO1998023284A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2121473C (en) * 1991-10-15 2001-05-01 Michael Mullarkey Methods and compositions for treating allergic reactions
WO1993019777A1 (en) * 1992-03-30 1993-10-14 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
DK0817847T4 (da) * 1995-03-23 2009-10-05 Immunex Corp IL-17-receptor
US5830655A (en) 1995-05-22 1998-11-03 Sri International Oligonucleotide sizing using cleavable primers
DE19782095T1 (de) 1996-11-06 2000-03-23 Sequenom Inc DNA-Diagnose auf der Basis von Massenspektrometrie
JP2001524808A (ja) 1996-12-10 2001-12-04 ジーントレイス・システムズ・インコーポレイテッド 放出可能な不揮発性の質量標識分子
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US20050147609A1 (en) * 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
EP1022027A1 (de) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Antagonisten von Tumornecrosefaktor und ihre Verwendungen gegen Endometriose
AU4684000A (en) * 1999-04-27 2000-11-10 Antibody Systems, Inc. Compositions containing tetracyclines for treating hemorrhagic virus infections and other disorders
MXPA03003407A (es) * 2000-10-18 2004-05-04 Immunex Corp Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.
US7708741B1 (en) 2001-08-28 2010-05-04 Marctec, Llc Method of preparing bones for knee replacement surgery
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US20040136992A1 (en) * 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
US20040063612A1 (en) * 2002-09-26 2004-04-01 Manssur Yalpani Neuroprotective agents
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CN101426268B (zh) * 2007-11-02 2010-08-25 大唐移动通信设备有限公司 导频资源分配方法、系统和设备
JP2011519911A (ja) 2008-05-05 2011-07-14 ノヴィミュンヌ エスア 抗ｉｌ１７ａ／ｉｌ−１７ｆ交差反応抗体及びその使用方法
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
NZ601125A (en) 2010-01-15 2014-08-29 Kirin Amgen Inc Antibody formulation and therapeutic regimens
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230742A (en) 1987-02-02 1993-07-27 A. E. Staley Manufacturing Co. Integrated process for producing crystalline fructose and high-fructose, liquid-phase sweetener
US5319071A (en) 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5416013A (en) 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
US5464938A (en) 1990-04-09 1995-11-07 Immunex Corporation Isolated viral protein TNF antagonists
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5359039A (en) 1993-07-09 1994-10-25 Immunex Corporation Isolated poxvirus A53R-equivalent tumor necrosis factor antagonists
US5594106A (en) 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
DK0817847T4 (da) 1995-03-23 2009-10-05 Immunex Corp IL-17-receptor
US5744340A (en) * 1995-06-09 1998-04-28 Schering Corporation Expression of human inducible nitric oxide synthase

Also Published As

Publication number Publication date
AU7408998A (en) 1998-06-22
ES2326347T3 (es) 2009-10-07
EP0959897B1 (de) 2009-04-22
EP0959897A1 (de) 1999-12-01
EP0959897A4 (de) 2002-01-30
WO1998023284A1 (en) 1998-06-04
DE69739375D1 (de) 2009-06-04
JP2001506982A (ja) 2001-05-29
US6083906A (en) 2000-07-04

Similar Documents

Publication Publication Date Title
DE69739375D1 (de) Verfahren zur regulierung der stickstoffmonoxid-erzeugung
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
AU2002239544A1 (en) Compositions and methods enabling a totally internally controlled amplification reaction
DE69703547D1 (de) Dauerhafte, niedrige oberflächenenergie aufweisende verbindungen und gegenstände, vorrichtungen und verfahren zur verwendung davon
DE59703977D1 (de) Verfahren zur stabilisierung des gasflusses in wasserführenden erdgaslagerstätten und erdgasspeichern
ID23731A (id) Metode dan aparatus untuk menambah perolehan karbon dioksida
DE59710284D1 (de) Vorrichtung und verfahren zur kombinierten reinigung und kompression von co-haltigem wasserstoff sowie ihre verwendung in brennstoffzellenanlagen
EP1035848A4 (de) Susstituierte alkanhydroxamisaeure und verfahren zur verminderung des tnf-alphaspiegels
ATE420432T1 (de) Verfahren und vorrichtung zur prädiktiven quantisierung von stimmhaften sprachsignalen
IL151149A0 (en) Zinc finger domains and methods of identifying same
DE69941744D1 (de) Verfahren zur Reduzierung des Metallgehalts in fluorhaltigem Polymer
ATE290375T1 (de) Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen
EE200100095A (et) Gaasi odoreerimise meetod
NL1006031A1 (nl) Lineaire vermogensversterkingsinrichting en -werkwijze.
DE59800649D1 (de) Vorrichtung und Verfahren zum Starten der Vorrichtung zur Erzeugung von wasserstoffreichem Gas
DK0803020T3 (da) Befæstigelse af forstærkningslameller
DE59812769D1 (de) Mikroorganismus, verfahren zur gewinnung desselben sowie futtermittelzusatz
DE69621499D1 (de) Kalkulator zur Abschätzung der Maximalwahrscheinlichkeits-Abfolge und Verfahren hierfür
DE69819438D1 (de) Verfahren zur Spracherkennung
DE69703201D1 (de) Hydroxyamidinderivate verwendbar als stickoxidsynthese inhibitoren
DE69823562D1 (de) Initiatorsystem sowie damit hergestellte polymerisierbare zusammensetzungen
DE60107416D1 (de) Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion
DE69908723D1 (de) Verfahren und Vorrichtung zur Sprachsynthese, sowie Speichermedium
DE69901076D1 (de) Lineares Trien sowie Copolymer davon
ATE483724T1 (de) Verfahren zur erhöhung der ausbreitung von b- zellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties